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Abstract 
Background: Patient-reported outcome measures are increasingly used by clinicians to support communication in 
telephone- or face-to-face consultations with patients. A renal disease questionnaire has been developed, but not suf-
ficiently evaluated through clinimetrics in clinical setting. Hence, we aimed to evaluate the content validity, construct 
validity and the test–retest reliability of a renal disease questionnaire to be used for clinical decision-making.
Methods: A content, construct validity and test–retest reliability study was conducted in 3 nephrology outpatient 
clinics in Central Denmark Region, Denmark. Content validity (face validity, comprehensibility and relevance) was 
assessed among 8 patients and 6 clinicians. Reliability was assessed by asking outpatients with chronic kidney disease 
to complete the questionnaire twice. Reliability was assessed by kappa statistics and agreement by percentage. Con-
struct validity was determined using 4 a priori defined hypotheses and comparing 2 known groups.
Results: Five new domains emerged, 6 items were rephrased and 3 items were removed following the content valid-
ity test. A total of 160 patients completed the questionnaire with median 8 days (IQR 2 days) between assessments. 
The test–retest reliability parameters of the single items in the questionnaire were substantial to almost perfect as all 
the observed weighted kappa values ranged from 0.61 to 0.91, 95% CI (0.34 to 0.95). In total, 61% of the single items 
showed almost perfect agreement. In total, 3 of the 4 hypotheses were accepted and 44% of the items showed satis-
fying known-group discriminative validity.
Conclusion: A renal disease questionnaire used for clinical decision-making in outpatient follow-up showed accept-
able content validity and substantial to almost perfect reliability. Sufficient construct validity was not established. 
Incorporating the questionnaire into routine clinical practice may improve the evaluation of disease burden in 
patients with chronic kidney disease.
Plain English summary: We ask patients with chronic kidney disease (CKD) in Central Region Denmark to complete 
a questionnaire before each outpatient visit. The answers they provide are used to support communication with 
their health care provider. A questionnaire requires testing to ensure it can accurately capture important information 
about patient’s symptoms and quality of life. When questionnaires are used to support communication between 
patients and health care professionals, they need to have good measurement properties. This means they need to 
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Background
Chronic kidney disease (CKD) significantly impacts 
general health and well-being [1]. Patients with CKD 
are commonly frail, due to substantial comorbidity 
and significant symptom burden [1, 2]. The severity of 
CKD is categorized: CKD stages 1-3a are anticipated to 
be largely asymptomatic. However, in CKD stages 3b, 
4 and 5, the symptom burden increases [3]. Common 
symptoms include fatigue, loss of appetite, pruritus, 
restless legs and cognitive dysfunction [2, 4, 5].
In Denmark, outpatient follow-up in patients with 
CKD stage 3b-5 has traditionally been based on regular 
face-to-face consultations. However, since 2012, there 
has been a growing interest in measuring and using 
patient reported outcomes (PROs) for remote data cap-
ture [6–8]. PRO measures capture information about 
a patient’s health status directly from the patient [9]. 
PRO measures provide important information regard-
ing the patients’ perspective on the degree and impact 
of disease symptoms [10]. Recent studies support the 
use of PRO measures in clinical practice with improved 
shared decision-making [11, 12], patient-clinician com-
munication [13–16], promoting accuracy of symptom 
assessment [17], and patient self-management [18–
20]. Remote PRO data may also help in managing use 
of healthcare resources [21–23]. Several PRO instru-
ments used to monitor health status among patients 
with CKD have been evaluated [24] and previous stud-
ies have explored the implementation of PRO instru-
ments in a pre-dialysis population [25–27]. The Kidney 
Disease Quality of Life-36 (KDQOL-36) questionnaire 
has been recommended in pre-dialysis patients, even 
though it was developed for patients in dialysis care 
[24, 28]. The KDQOL-36 has been validated in a Danish 
setting, but lacks evidence to support important prop-
erties on internal consistency, reliability and construct 
validity. Moreover, it is only tested in patients on dialy-
sis in a Danish setting. [29]. Another study developed 
a clinical questionnaire [27], however this study was 
small and had several limitations such as low evidence 
for reliability and validity. Thus, there is a need for 
development of a reliable disease-specific instrument 
accurately measuring the most common symptoms, 
such as fatique, pruitus, nausea and loss of appetite, 
experienced by patients with CKD [1, 2].
In 2012, a renal disease questionnaire (RDQ) was 
developed and used to monitor general health status and 
to facilitate communication between patients and health 
professionals in the 3 nephrology outpatient clinics in 
Central Denmark Region with 858,083 inhabitants cor-
responding to 15% of the Danish population [30]. The 
RDQ was developed in close cooperation between clini-
cians and patients, and was tested for face-validity [31]. 
However, validity and reliability are essential psychomet-
ric properties for any measure [32, 33], and the ability of 
a PRO instrument to improve decision-making in clinical 
practice relies on the ability of the instrument to accu-
rately capture the burden of disease or treatment [32]. 
The validity and reliability of the final questionnaire has 
not yet been evaluated, which is pivotal in the develop-
ment of the instrument [32]. Therefore, we needed to 
demonstrate if the RDQ shows sufficient validity and is 
reliable so it may be deployed in clinical practice. This 
psychometric testing represents a first step toward sup-
porting the questionnaire’s use in clinical practice [34].
Aims
We aimed to evaluate the face and content validity and 
test–retest reliability of the single items included in the 
questionnaire used as support in clinical decision-mak-
ing in nephrology outpatient follow-up. Furthermore, 
we aimed to evaluate the construct validity of burden of 
symptoms by establishing known group validity.
Methods
Renal disease questionnaire (RDQ)
Historical development
The development of the questionnaire was iterative and 
based on consensus decision-making and face-to-face 
meetings with patients and clinicians. The process initi-
ated in 2012 and was divided into two phases: (1) defin-
ing aim, content and construction of the questionnaire; 
and (2) pilot-testing. The renal disease questionnaire 
(RDQ) was implemented into clinical practice and was 
adapted based on experiences from clinical practice once 
yearly until 2017.
be: (1) trustworthy, (2) relevant to a patient’s health condition, (3) consistent and produce stable results every time. 
We explored the measurement properties of a questionnaire designed to be used in the face-to face outpatient visits 
for patients with CKD. We found that the questionnaire captured consistent and stable results. Using this question-
naire may help health care professionals to assess the patients´ burden of symptoms with a more patient-centered 
approach. Potentially, the use of the questionnaire will increase the patients´ ability to cope with their symptoms and 
strengthen patients´ involvement in the clinical decisions concerning their treatment.
Keywords: Renal insufficiency, Ambulatory care, Patient reported outcome measures, Reproducibility of results
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Content
The content was based on existing validated PRO instru-
ments or items. Additionally, ad hoc items were devel-
oped if existing instruments or items were not available. 
This process was supported by nephrology specialists, 
a systematic literature search, and patient interviews. 
The prototype RDQ included information specific to 
aspects of daily life with CKD. The instrument consisted 
of 3 items regarding general health and fatigue from the 
Short Form-36 (SF-36) [35, 36]. SF-36 is a generic ques-
tionnaire with 8 subscales measuring physical and men-
tal health [36], and the psychometric properties of the 
Danish SF-36 have been well documented [35, 37]. Seven 
items regarding lack of appetite, pruritus, dizziness, nau-
sea, dyspnoea, reduced concentration and memory from 
the Kidney Disease Quality of Life Short Form (KDQOL-
SF) [28] were included, some of which have been modi-
fied after the pilot test. The KDQOL-SF questionnaire 
combines the generic SF-36 scale and disease-specific 
components for assessing health-related quality of life in 
CKD patients [28]. Additionally, 5 items including fre-
quent nocturnal urination, daily activities, worries about 
the future, oedema, and sleeping disorder were selected 
from the European Organization for Research and Treat-
ment (EORTC) QLQ questionnaires [38] designed to 
measure quality of life in patients with cancer. How-
ever, these items are consistent with symptoms reported 
among patients with CKD [2, 5]. Finally, ad hoc items 
concerning e.g. drug adherence, blood pressure and 
weight were added.
Clinical use of the questionnaire
The questionnaire is used to support clinical decision-
making and communication in nephrology outpatient 
clinics. A clinical expert group has assigned each item 
response into 3 colours: red, yellow or green. Red indi-
cates that the patient is experiencing a particular prob-
lem within this domain; Yellow indicates that the patient 
is experiencing slight to moderate problems; and green 
indicates that the patient is not experiencing any prob-
lems within the domain. A graphical PRO overview of 




In total, 8 patients participated in cognitive interviews 
and 6 clinicians participated in a focus group interview 
in order to evaluate face and content validity. Patients 
attending the nephrology outpatient clinics at Aarhus 
University Hospital and Central Regional Hospital, 
Viborg, were invited. Patients were selected purposively 
in order to maximise the variation of informants in 
terms of CKD duration, age, gender and experience 
of using the RDQ in the clinical encounter. Clinicians 
attending the focus group interview were selected 
based on their role in the organisation. Hence, par-
ticipants from the management team, physicians and 
nurses were represented.
Construct validity and test–retest reliability
The target population was patients who had answered 
the questionnaire prior to a visit to the outpatient 
clinic within the previous 5  years. Inclusion criteria 
were age ≥ 18, CKD stage 3b-5 [3] in pre-dialysis care, 
as these patients often experience the symptoms asked 
in the questionnaire [2, 39–41]. All patients were con-
tacted by “e-boks”, a secure electronic mailbox for all 
citizens in Denmark. The reliability analysis consisted 
of 160 responders of test 1 and test 2 and the construct 
validity analysis was based on the 278 responders of test 
1. Figure 1 shows the inclusion of study participants.
Questionnaire(test 1) send to
eligible chronic kidney disease
(CKD) patients stage 3b-5
n = 599
Non responders (test 1)
n = 321
Questionnaire (test 2) send to
responders (test 1)
n = 278
Non responders (test 2)
n = 74
Study population,
CKD patients stage 3b-5,
n = 160
Responders test 1 & 2
n = 204
Excluded
Change in health, n = 16
Contact to clinic, n = 28
Fig. 1 Inclusion of study participants
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Procedure and analyses
Methods to evaluate content and face validity
Content validity includes face validity and reflects 
whether the items in a questionnaire represent the con-
cept of interest [42]. The purpose of cognitive inter-
viewing was to assess the patients’ and clinicians’ 
comprehension of the separate items and the complete 
PRO instrument against the intended meaning. Com-
prehensibility and usability, relevance and deficits of 
the questionnaire were assessed in one-to-one semi-
structured interviews with 8 patients and 6 clinicians 
participating in a focus group. Table 1 shows the charac-
teristics of the participants in the content and face valid-
ity analyses.
Sampling followed the criteria of ‘sampling to redun-
dancy’; that is to say interviewing people until no new 
information emerges [43]. Methodologically, the prac-
tice of cognitive interviewing patients as well as clini-
cians comprised 2 general techniques; “thinking aloud” 
and “verbal probing” while completing the question-
naires and also commenting on the layout and implica-
tion to clinical practice, following an interview protocol 
[44, 45]. All interviews were recorded and transcribed 
verbatim according to the interview guides shown in 
an Additional file  1. The researcher BEG, who is also a 
skilled interviewer and experienced nurse within the field 
of clinical nephrology, carried out the interviews and 
transcriptions.
Construct validity
Construct validity is defined by the COnsensus-based 
Standards for the selection of health status Measurement 
INstruments (COSMIN) panel as the degree to which the 
scores of a measurement instrument are consistent with 
hypotheses, e.g. with regard to internal relationships or 
differences between relevant groups [46]. According to 
the COSMIN criteria, the construct validity of an instru-
ment is sufficient when 75% of the predefined hypotheses 
are confirmed in a sample of at least 50 patients [42]. We 
used the Wilson and Cleary conceptual model of health 
status as a theoretical framework to explain how con-
structs may be related and how symptom status affects 
the functional status and the patients´ general health per-
ception. Each symptom represents a construct, which is a 
measure of a symptom [47]. In the present study, the con-
struct of interest was the symptoms perceived by patients 
with CKD and the impairment of the physical function. 
Construct validity was assessed by comparing associa-
tions between selected single PRO measures and similar 
or divergent health-related outcomes.
Based on previous findings [7, 48, 49], we hypothesised 
that:
The correlation between nocturnal awakening 
and low daily activity would be moderate to good 
(r =  > 0.50)
The correlation between high self-rated health and 
low renal function would be negligible (r = 0.10–
0.30)
The correlation between lack of appetite and feel-
ing aversion to food would be moderate to good 
(r = > 0.50)
High Quality of life (EQ-5D) would correlate moder-
ately to good (r = > 0.50) with high daily activities
We used Spearman rank correlation coefficients due to 
the ordinal nature of the items. Correlations were con-
sidered as follows: 0.10 to 0.30 = little or no relationship, 
0.30 to 0.50 = fair relationship, 0.50 to 0.70 = moderate 
to good relationship, and > 0.70 = good to excellent rela-
tionship [50]. The shape and direction of the relation-
ship between the selected items will be computed in 
Stata graph bars and reported. Finally, we assessed the 
capacity of each item in the questionnaire to discrimi-
nate between 3 subgroups of patients; patients in CKD 
stage 3b (n = 141), CKD stage 4 (n = 69) and CKD stage 
5 (n = 23) [51]. Due to the low number of participants in 
stage 5, we combined participants in stage 4 and 5 in the 
analyses. We described the proportion and percentage of 
participants in each category and used the Mann–Whit-
ney test for unequal distributions in these groups [46].
Reliability
Reproducibility was assessed by examining the degree of 
agreement between scores on the measure at first assess-
ment and when reassessed [46]. The final version of the 
Table 1 Characteristic of the participants in the face and 
content validity study
N (%)
Patients, semi-structured interviews (N = 8)
 Gender, men 6 (80)
 Age, median [min;max] 72 [59;86]
 Aarhus University Hospital 5 (62)
 Central Regional Hospital, Viborg 3 (38)
 Years followed-up in the outpatient clinic, median [min;max] 4 [1;8]
Clinicians, focus group (N = 6)
 Gender, men 1 (16)
 Age, median [min;max] 51 [44;61]
 Nurse 3 (50)
 Physician 2 (33)
 Team manager 1 (17)
 Years of experience, median [min;max] 14 [6;27]
Aarhus University Hospital 6 (100)
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RDQ (Additional file  2) following the validity analyses 
formed the basis for conducting the test–retest analysis. 
Data collection took place from May to August 2019. Par-
ticipants completed the questionnaire at 2 time points. 
By e-mail, patients were informed of the study details, 
and asked to complete the questionnaire (named ‘test 1’). 
Non-responders received a reminder after 2  days. Sub-
sequently, the same questionnaire (named ‘test 2’) was 
sent to the responders of ‘test 1’. No reminders were sent. 
Time between ‘test 1’ and ‘test 2’ was 7  days. The test–
retest study was performed in patients with stable dis-
ease activity, i.e. patients who in the test 2 questionnaire 
answered “somewhat the same” to the question: “Com-
pared to a week ago, how is your health all in all now?” 
and “no” to the question: “During the past week have you 
been in contact with the outpatient clinic?”. Test–retest 
reliability and agreement were assessed within the item 
categories. In nominal and ordinal data, respectively 
unweighted and weighted kappa statistics with squared 
weights were used to assess reliability [32]. The 95% con-
fidence intervals (CI) for weighted kappa values were 
measured using non-parametric bootstrap methods with 
1000 replications [52]. The kappa agreement was inter-
preted as follows: < 0.2 (slight), 0.21–0.4 (fair), 0.41–0.60 
(moderate), 0.61–0.80 (substantial), and 0.81–1.0 (almost 
perfect) [53]. Perfect agreement (identical responses at 
the two time points) and proportion of agreement was 
used to assess agreement measures [32]. A sensitivity 
analysis with patients who had been in contact with the 
outpatient clinic or who had reported a change in health 
condition was performed.
Other analyses
Descriptive statistics was presented as means and stand-
ard deviations (SDs), medians and interquartile ranges 
(IQR) or numbers (%) according to the distribution. Dif-
ferences between responders and non-responders were 
evaluated by  X2 test for categorical variables and the 
Mann–Whitney test for continuous variables with non-
normal distributions. Lack of response was assessed for 
all items and was considered unacceptable if data was 
missing in more than 5% of an item category. Floor and 
ceiling effects were assessed and considered present if a 
high proportion (> 15%) of the respondents had a score 
at the lower or upper end of the scale [34]. We used the 
Charlson Comorbidity Index to estimate the burden of 
comorbidity [54, 55]. Information on the patients’ diag-
nosis and renal function was obtained from the Hospi-
tal Business Intelligence Register in Central Denmark 
Region [56].
A formal sample size calculation was not carried 
out in the present study due to the pragmatic design, 
where we approached all patients who had answered 
the questionnaire prior to a visit to the outpatient clinic 
within the previous 5 years. The overall recommendation 
regarding sample size in reliability studies is to include at 
least 50 patients [34]. A 5% significance level using two-
sided tests was chosen, and STATA 16 was used for all 
analyses. This study followed the requirements from the 
COSMIN Risk of bias checklists for content validity, reli-
ability and hypotheses testing for construct validity [57]. 
See checklist (Additional File 3).
Results
Content and face validity
The full results of the cognitive interviewing are shown 
in Additional File 4: Table  S1. Three items in the ques-
tionnaire were removed, 6 questions were rephrased and 
5 new items emerged. Clinicians reflected on the length 
of the questionnaire and relevance for the patients and 
underlined the importance of a short and concise ques-
tionnaire. Patients highlighted the importance of know-
ing the purpose of the questionnaire. The majority of 
patients found the content of the questionnaire relevant, 
and no critical comprehension difficulties were identified. 
The time used to fill in the questionnaire did not raise any 
criticism, average time for completion was 8  min (min 
4; max 13). Upon revision, the final version of the RDQ 
(Additional file  2), provided the basis for psychometric 
analyses.
Test–retest reliability and agreement of single items
In total, 599 questionnaires were sent out to patients at 
time point 1, and 278 questionnaires were sent out at 
time point 2. Questionnaire returns were 278 (46%) at 
time point 1 and 204 (73%) at time point 2, giving a total 
response rate of 34%. After exclusion of patients report-
ing a change in health (n = 16) and those who had been 
in contact with the outpatient clinic (n = 28), the study 
population consisted of 160 patients with CKD stage 
3b-5 (Fig. 1). Patient characteristics are shown in Table 2.
Non-responders were more likely to be younger 
(p = 0.04) and female (p < 0.001) (Table  2). The median 
age was 69 (IQR 18.5) years. In total, 67% reported suf-
fering from other conditions, which affected their health 
besides CKD, such as arthritis, diabetes, pain, heart fail-
ure and cancer. The mean burden from comorbidity from 
the CCI was 1.31 (SD 1.5, range 0–8).
The median response time from test 1 to test 2 was 
8 days (IQR 2, range 5–28 days). The test–retest reliabil-
ity parameters of the single items in the RDQ were sub-
stantial to almost perfect as all the observed weighted 
kappa values were above 0.61, 95% CI (0.34 to 0.95). 
Perfect agreement ranged from 55 to 96% in each sin-
gle item. Totally, 61% of all items showed almost per-
fect agreement, as shown in Additional file  5: Table  S2. 
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The sensitivity analysis including patients (n = 204) who 
had contact with the outpatient clinic or who reported 
a change in health condition showed slightly reduced to 
perfect agreement, ranging from 52 to 92% and kappa 
values between 0.56—0.87, 95% CI (0.37 to 0.92), as 
shown in Additional file  6: Table  S3. Missing responses 
were less than 3% in all items. For the majority of items, a 
skewed distribution was observed with high proportions 
of more than 15% at the upper or lower end of the scale, 
as shown in Additional file 5: Table S2.
Construct validity
Data supported the hypothesis in 3 of the 4 a priori con-
structed hypotheses. The results of hypotheses testing are 
shown in Table 3.
The distribution of self-reported characteristics to 
show independence between 2 known groups determin-
ing the discriminative validity is presented in the Addi-
tional file  7: Table  S4. In total 10 of the 23 items (44%) 
showed satisfying known-group validation in the RDQ.
Discussion
This is the first study investigating some of the psycho-
metric properties of a disease-specific renal disease 
questionnaire (RDQ) used to support clinical decision-
making in outpatient clinics. Face and content validity 
was found acceptable. In total, 44% of the items showed 
satisfying known-group discriminative validity and 3 of 
the 4 a priori hypotheses were accepted, demonstrat-
ing the initial step of establishing construct validity. The 
test–retest reliability kappa values of the single items 
in the questionnaire were substantial to almost perfect. 
In total, 61% of the single items showed almost perfect 
agreement.
Content and face validity
Patients emphasised the importance of knowing the 
purpose and clinical use of the questionnaire, which is 
crucial when implementing PRO measures in a clini-
cal setting [11, 58]. Similar findings have been reported 
in previous studies [18, 19, 59, 60]. A recent systematic 
review found strong evidence supporting internal con-
sistency and moderate evidence for construct validity 
for the KDQOL-36 in pre-dialysis patients [24], which 
formed the basis of the questionnaire in our study. The 
Table 2 Patient characteristics measured at time for test 1 in 
responders and non-responders in test 2 among outpatients 
with chronic kidney disease (n = 555)
Patients reporting change in health and patients who have been in contact with 
the clinic are excluded
a Non-responders (n = 74) in test 2. CCI = Charlson Comorbidity Index; 
eGFR = estimated glomerular filtrations rate (renal function); EQ-5D = European 
Quality of life 5-Dimensions; IQR = Inter Quartile Range; p-value = Chi-squared 









Gender, men 115 (71) 225 (57) < 0.001
Age, year median [IQR] 69 [18.5] 56 [30] 0.04b
eGFR, median [IQR] 28.2 [10] 33,4 [10] 0.78b
CCI, mean (SD) 1.31 (1.5) 1,28 (1.31) 0.82
 Low 0 49(30) 169 (42)
 Medium 1–2 88(55) 175 (44)
 High > 2 23(15) 51 (14)
Quality of life (EQ-5D)a
Median, [IQR] 0.80 [30] 0.80 [20] 0.97b
General  healtha
 Excellent 16 (10) 5 (7) 0.76b
 Very good 37 (23) 22 (30)
 Good 68 (42) 30 (40)
 Fair 36 (23) 15 (20)
 Poor 3 (2) 2 (3)
Table 3 Construct validity:  correlationsa between selected PRO items among 278 outpatients with chronic kidney disease
a Spearman correlation coefficients (r) were calculated
b n = 233
Daily activities Renal function Feeling 
aversion to 
food
Quality of life Interpretation of correlation (r) Shape of relationship
Nocturnal awakening r = 0.31
p < 0.0001
Hypothesis rejected Negative linear
Self-rated health r = 0.19b
p = 0.004
Hypothesis accepted Negative linear
Lack of appetite r = 0.77
p < 0.0001
Hypothesis accepted Negative linear
Daily activities r = 0.58
p < 0.0001
Hypothesis accepted Negative linear
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scale has been validated in a Danish setting, but has not 
yet reached recommended values [29]. The outpatient 
clinics needed an instrument to support clinical deci-
sion-making in terms of monitoring patients’ health sta-
tus; this means focusing on the most relevant questions 
from a clinician- and patient viewpoint [15]. Consist-
ent with previous studies [11, 61], our cognitive inter-
views supported that a questionnaire needs to address 
key issues and not be too comprehensive. The use of 
multiple ‘single-domain’ items within a measure allows 
the production of a short tool which, when compared 
to existing PROs, may be capable of measuring several 
patient-important domains using a less time-consuming 
format for patients and clinicians [62]. In contrast, single-
domain items seem to lose sensitivity and are less reliable 
for tracking individual changes. However, the constructs 
measured in this questionnaire are unidimensional. 
Hence, a single item scale is considered appropriate [62]. 
Involving clinicians and patients in the evaluation of the 
questionnaire has potentially increased the feasibility and 
clinical relevance of the selected PRO measures.
Construct validity
Evaluation of construct validity includes the degree to 
which a measure correlates with other measures to which 
it is similar and diverges from measures that are dissimi-
lar [46]. Since no comparative instrument was available, 
we formulated hypotheses based on prior findings in the 
literature. The selected PRO measures in the analyses 
of construct validity were assumed to be the most clini-
cally relevant when monitoring the progression of CKD 
[1]. With a 75% rate of confirmed predefined hypotheses 
in this study of 278 patients with CKD, according the 
COSMIN quality criteria we reached sufficient construct 
validity [42]. However, as each item in the questionnaire 
represents a unique construct and therefore needs to 
be validated with its own hypothesis, we cannot claim 
to have reached sufficient construct validity. However, 
construct validity is a lengthy, ongoing process [63, 64], 
and this paper only demonstrates the initial step towards 
establishing construct validity. In total, 10 of the 23 items 
(44%) in the RDQ showed satisfying known-group valida-
tion. Unfortunately, we needed to dichotomies data due 
to a low number of participants in the stage 5 group, and 
even though our findings are concurrent with the avail-
able literature [2, 7, 65], this may potentially have blurred 
the results and have violated the overall findings. Appar-
ently, the symptom score varies widely in patients with 
the comparable renal function. Several studies suggest 
that also social, psychological determinants and comor-
bid conditions play an important role in symptom devel-
opment and burden [66–68]. Generally, QoL deterioate 
when renal funcion declines [69]. However, the relation 
between kidney disease specific symptoms and decline 
in renal function is not straightforward and litterature 
on this is scarce [70]. In the EQUAL group, they found 
a faster decline in renal function to be associated with 
higher symptom burden [66]. This may play a role when 
known group validation is conducted, whilst we cannot 
rule out some adaptation to long-term CKD. During 
the development process, redundant items should have 
been added to the questionnaire for validation purposes 
[63]. Unfortunately, this was not feasible in the design of 
this study. It should therefore be acknowledged that fur-
ther research is required to provide additional evidence 
around construct validity. Hence, the four a priori chosen 
hypotheses from the selected items do not reflect on the 
construct validity of items not included in the hypoth-
eses. However, this questionnaire serves as a clinimetric 
scale and does not necessarily need to satisfy the same 
requirements as a psychometric scale [63]. From a clini-
metric perspective, a single-item measure could be use-
ful as long as it discriminates between different groups of 
patients and reflects clinically relevant changes over time 
[71]. However, further psychometric analysis investigat-
ing the validity of single items will be needed before full 
construct validity is established.
Reliability
Overall, we found that test–retest reliability was con-
sidered substantial to almost perfect in all the included 
items in the RDQ, although some items showed only 
fair or moderate values at the lower end of the confi-
dence intervals. However, kappa values are influenced 
by skewed distribution, number of classes, and system-
atic differences between the 2 measurements [72]. A 
skewed distribution leads to a lower extent of real agree-
ment due to a higher fraction of chance agreement [72]. 
A skewed distribution in several items in the question-
naire was shown, probably due to a homogeneous pop-
ulation with stable disease activity and low symptom 
burden. This skewed distribution may have resulted in 
an underestimation of the kappa values [72]. A skewed 
distribution was observed with high proportions of more 
than 15% at the upper or lower end of the scale. Poten-
tially, this could affect the reliability and the ability to 
distinguish patients with the lowest or highest score 
from each other [42]. From a clinician viewpoint this 
was considered acceptable as the items in the question-
naire represent alert symptoms, which indicate a poten-
tial hazard or condition requiring  special attention. We 
found the lowest kappa values in the items concerning 
medication adherence 0.61 (95% 0.34; 0.83) and vomit-
ing showing kappa value at 0.69 (95% 0.32; 0.90). How-
ever, the agreement in both items was high; > 98%. The 
discrepancy between level of agreement and kappa may 
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be caused by an unequal distribution and ceiling effect. 
This illustrates that kappa is affected by the prevalence 
of the measured event and distribution of item scores 
[72]. The outliers with low agreement represented items 
as fatique (55% perfect agreement) and restless legs (62% 
perfect agreement), which may be related to a certain day 
to day variation. Several potential threats related to the 
consistency of a PRO measurement may occur. A long 
interval increases the risk of a real change in patient sta-
tus and a short interval increases the risk of recall bias 
[63]. The study population consisted of frail elderly peo-
ple with a high level of comorbidity; this required that 
the interval between the assessments should be short 
due to variation in health. We had a time difference at 
8  days (IQR 2  days) between test 1 and test 2, which is 
within the recommendation from the literature [32, 34]. 
A real change in the patient´s health status between the 
2 time points of measures might cause a potential error 
related to the consistency of a PRO measurement [63]. 
However, we excluded patients who reported a change in 
health status which strengthened our results. According 
to COSMIN framework, reliability needs to be tested in 
patients who are stable in the interim period on the con-
struct to be measured [34]. Potentially, bias would occur 
if the patients failed to report a change in disease status 
due to recall problems. Another strength in the analyses 
was that the questionnaires were completed independent 
of a visit in the clinic and patients who had a visit at the 
outpatient clinic were excluded from the analyses (Fig. 1). 
If the disease status had changed upon treatment at the 
outpatient clinic, it might have induced risk of bias, as 
this represents responsiveness [34]. We performed sen-
sitivity analysis including patients with a change in health 
condition or having contact with the outpatient clinic 
and found a tendency towards decreased reliability as 
expected.
A limitation in this study was the risk of selection 
bias. The response rate was only 34%, which might have 
been caused by the pragmatic design. This only allowed 
us to approach a known group of patients without any a 
priori knowledge of their present renal function. Com-
pared to non-responders, there were more elderly and 
more men among responders, whereas no significant 
difference in renal function was observed. A study pop-
ulation that does not represent the targeted population 
may challenge generalisation of the results. However, 
the differences between responders and non-respond-
ers are not likely to be clinically important. Importantly, 
the presence of some selection bias cannot be excluded, 
thus hampering the external validity of our findings. 
A use of reminders at test 2 could have increased the 
overall response rate. However, the participants did 
not receive reminders at test 2 to ensure an acceptable 
interval length between the 2 measurement points in 
a test–retest study [42]. The mode of administration 
only included web responders, which could potentially 
induce selection bias. However, in recent years, the use 
of web-based questionnaires has increased dramatically 
[73]. This could potentially underestimate the reliabil-
ity parameters due to the homogeneous study popu-
lation. Yet, the study population represents the target 
population and the real-life environment and a mere of 
5% of the patients in the outpatient nephrology clinics 
responded to the questionnaire in a paper version.
Among the 3 main measurement properties domains 
in the COSMIN framework, we have investigated the 
validity and the reliability. The present study was not 
designed to evaluate responsiveness, which should 
be assessed in a longitudinal study. This would pro-
vide further evidence when using the RDQ to follow 
patients’ health status over time.
Incorporating this questionnaire into clinical practice 
may allow measurement of outcomes that may be more 
relevant to approximately 600–800 patients with CKD 
using this questionnaire. In the coming years we expect 
a more intense use of PRO measures in clinical practice 
[73], which highlights the importance of improving the 
quality of this PRO instrument.
Conclusion
This is the first study investigating some of the psycho-
metric properties of a disease-specific renal disease 
questionnaire (RDQ) used to support clinical deci-
sion-making in outpatient clinics. Our study shows the 
importance of including end users when developing a 
questionnaire for clinical use. It is fundamental that 
the questions asked reflect the needs of the clinicians 
and patients. We have demonstrated the initial step in 
establishing construct validity. However, the construct 
validity and discriminative ability should be further 
investigated in future studies. Overall, RDQ showed 
substantial to almost perfect test–retest reliability. Fur-
ther psycometric measurement properties and estab-
lishment of clinical responsiveness represents the final 
necessary steps before deploying this tool for use in 
clinical nephrology settings.
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